The obscure advisory committees at the heart of the U.S. drug pricing debate

Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc, Eli Lilly and Co and Teva Pharmaceutical Industries.

from Reuters: Health News https://reut.rs/2IQcxFd
via IFTTT